Comment on Hillis et al. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295–303

We have read the study by Hillis et al. (1) about N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the context of diabetes with great interest. After our publications on this topic (2,3) and the Casale Monferrato Study (4), this is now the third well-adjusted cohort showing the ability of NT-proBNP as a risk marker for cardiovascular disease in this setting. We agree that the clinical relevance still has to be proven in future trials. In particular, the question of whether biomarkers like NT-proBNP or troponin can identify subgroups of patients who benefit the most from therapy is of considerable importance. Due to limited resources, there are conflicts of interest between low-risk and high-risk patients. This, by the way, resulted …